BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $61

Benzinga Newsdesk www.benzinga.com Positive 89.2%

Neg 0% Neu 0% Pos 89.2%

BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $60 to $61.